Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Summary

The purpose of this study is to determine whether prostate cancer growth can be slowed in patients who receive Androgel® 1% at 10 gram dose.

Timeline

Start

2007-07

Primary completion

2010-11

Completion

2012-08

Publications

• Geynisman DM, Szmulewitz RZ, Stadler WM. A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer. Eur Urol. 2012 Nov;62(5):864-6. doi: 10.1016/j.eururo.2012.08.030. Epub 2012 Aug 25. No abstract available.

Drugs

Indications